LOXL1 gene polymorphisms are associated with exfoliation syndrome/exfoliation glaucoma risk: An updated meta-analysis

Background Single nucleotide polymorphisms (SNPs) in the gene encoding LOXL1 are risk factors for exfoliation syndrome and exfoliation glaucoma. This meta-analysis comprehensively investigated the association between LOXL1 gene polymorphisms (rs1048661, rs3825942, and rs2165241) and the risk of exfoliation syndrome/exfoliation glaucoma (XFS)/(XFG). Methods All eligible case-control studies, published before August 17, 2020, were searched on Medline (Ovid), PubMed, CNKI, EMBASE, and Wanfang databases. Results In total, 5022 cases and 8962 controls were included in this meta-analysis. Significant associations between LOXL1 gene polymorphisms and XFS/XFG risk was observed in the disease types-based subgroups. In addition, in the subgroup analysis of ethnicity, positive associations between LOXL1 gene polymorphisms (rs1048661, rs3825942, and rs2165241) and XFS/XFG risk were found in Caucasians. Furthermore, rs1048661 and rs3825942 polymorphisms were related to XFS/ XFG risk in Asians; however, no significant association was observed between the LOXL1 gene rs2165241 polymorphism and XFS/XFG risk in Asians. In addition, rs1048661 and rs3825942 correlated with XFS/XFG susceptibility in Africans. Conclusions Our results implicate LOXL1 gene polymorphisms as XFS/XFG risk factors, especially in Caucasians.

Quantitative assessment of the association of polymorphisms in the metallothionein 2A gene with cancer risk

Objective The aim of the study was to quantitatively assess the association of metallothionein 2A ( MT2A) polymorphisms rs28366003 and rs1610216 with cancer risk. Methods Crude odd ratios (OR) with 95% confidence intervals (CI) were used to estimate associations of the polymorphisms with cancer risk. Results Six eligible case-control studies with 1899 cases and 2437 controls focused on rs28366003, and three of those six studies, with 548 cases and 926 controls, additionally focused on rs1610216. Pooled analysis showed that MT2A rs28366003 and rs1610216 were associated with cancer risk: (AG + GG) vs. AA, OR = 2.67; GG vs. (AG + AA), OR = 5.97; GG vs. AA, OR = 6.80; AG vs. AA, OR = 2.46; G vs. A, OR = 2.67 for rs28366003; and CC vs. (TC+TT), OR = 2.51; CC vs. TT, OR = 2.42 for rs1610216. Subgroup analysis based on ethnicity showed a significant association of rs28366003 with cancer risk in Asian and Caucasian populations. However, a significant association of rs1610216 with cancer risk was found only in the Asian population. Conclusion MT2A rs28366003 and rs1610216 polymorphisms were associated with cancer risk and might serve as genetic biomarkers for predicting cancer risk. However, larger studies are needed to confirm these findings.

Association of ABO Polymorphisms and Pancreatic Cancer/ Cardiocerebrovascular Disease: a Meta-analysis.

Background: ABO gene polymorphisms have been reported to be associated with the risk of multiple cancers and cardiocerebrovascular disease s. However, the results remained controversial. In this study, we conducted a systematic review and meta-analysis to clarify the association between two SNPs (rs505922 and rs657152) in ABO gene and cancers/ cardiocerebrovascular disease s. Method: All eligible case-control studies come from PubMed, Embase and Web of Science up to Jan. 1, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding associations. Sensitivity analysis, publication bias assessment, and heterogeneity test were performed using STATA 12.0. Results : A total of nineteen articles involving twenty-two case-control populations were included according to inclusion and exclusion criteria. Twelve populations (20,820 cases and 27,837 controls) were used to evaluate the relationship between rs505922 and overall cancers and nine populations (22,275 cases and 71,549 controls) were included to assess the association between rs505922 and cardiocerebrovascular diseases. The results showed a significant association between the rs505922 polymorphism and cancers (CvsT: OR=1.13, 95%CI=1.05-1.22, P =0.001), and cardiocerebrovascular diseases (OR=1.36, 95%CI=1.19-1.57, P <0.001). Five populations (8,660 cases and 10,618 controls) were included to evaluate association between rs657152 and cancers and five populations (8,105 cases and 6,712 controls) were included to estimate the relationship between rs657152 and cardiocerebrovascular diseases. The result of meta-analysis reveals that rs657152 was significantly associated with cancers (OR=1.18, 95%CI=1.13-1.23, P <0.001) and cardiocerebrovascular diseases (OR=1.54, 95%CI=1.24-1.92, P <0.001). Conclusion: Our study suggested that ABO polymorphisms might serve as a risk factor of pancreatic cancers and cardiocerebrovascular diseases.

Association of ABO Polymorphisms and Pancreatic Cancer/ Cardiocerebrovascular Disease: a Meta-analysis.

Background: ABO gene polymorphisms have been reported to be associated with the risk of multiple cancers and cardiocerebrovascular disease s. However, the results remained controversial. In this study, we conducted a systematic review and meta-analysis to clarify the association between two SNPs (rs505922 and rs657152) in ABO gene and cancers/ cardiocerebrovascular disease s. Method: All eligible case-control studies come from PubMed, Embase and Web of Science up to Jan. 1, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding associations. Sensitivity analysis, publication bias assessment, and heterogeneity test were performed using STATA 12.0. Results : A total of nineteen articles involving twenty-two case-control populations were included according to inclusion and exclusion criteria. Twelve populations (20,820 cases and 27,837 controls) were used to evaluate the relationship between rs505922 and overall cancers and nine populations (22,275 cases and 71,549 controls) were included to assess the association between rs505922 and cardiocerebrovascular diseases. The results showed a significant association between the rs505922 polymorphism and cancers (CvsT: OR=1.13, 95%CI=1.05-1.22, P =0.001), and cardiocerebrovascular diseases (OR=1.36, 95%CI=1.19-1.57, P <0.001). Five populations (8,660 cases and 10,618 controls) were included to evaluate association between rs657152 and cancers and five populations (8,105 cases and 6,712 controls) were included to estimate the relationship between rs657152 and cardiocerebrovascular diseases. The result of meta-analysis reveals that rs657152 was significantly associated with cancers (OR=1.18, 95%CI=1.13-1.23, P <0.001) and cardiocerebrovascular diseases (OR=1.54, 95%CI=1.24-1.92, P <0.001). Conclusion: Our study suggested that ABO polymorphisms might serve as a risk factor of pancreatic cancers and cardiocerebrovascular diseases.

Association of ABO Polymorphisms and Pancreatic Cancer/Cardiocerebrovascular Disease: a Meta-analysis

Background: ABO gene polymorphisms have been reported to be associated with the risk of multiple cancers and cardiocerebrovascular disease s. However, the results remained controversial. In this study, we conducted a systematic review and meta-analysis to clarify the association between two SNPs (rs505922 and rs657152) in ABO gene and cancers/ cardiocerebrovascular disease s. Method: All eligible case-control studies come from PubMed, Embase and Web of Science up to Jan. 1, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding associations. Sensitivity analysis, publication bias assessment, and heterogeneity test were performed using STATA 12.0. Results : A total of nineteen articles involving twenty-two case-control populations were included according to inclusion and exclusion criteria. Twelve populations (20,820 cases and 27,837 controls) were used to evaluate the relationship between rs505922 and overall cancers and nine populations (22,275 cases and 71,549 controls) were included to assess the association between rs505922 and cardiocerebrovascular diseases. The results showed a significant association between the rs505922 polymorphism and cancers (CvsT: OR=1.13, 95%CI=1.05-1.22, P =0.001), and cardiocerebrovascular diseases (OR=1.36, 95%CI=1.19-1.57, P <0.001). Five populations (8,660 cases and 10,618 controls) were included to evaluate association between rs657152 and cancers and five populations (8,105 cases and 6,712 controls) were included to estimate the relationship between rs657152 and cardiocerebrovascular diseases. The result of meta-analysis reveals that rs657152 was significantly associated with cancers (OR=1.18, 95%CI=1.13-1.23, P <0.001) and cardiocerebrovascular diseases (OR=1.54, 95%CI=1.24-1.92, P <0.001). Conclusion: Our study suggested that ABO polymorphisms might serve as a risk factor of pancreatic cancers and cardiocerebrovascular diseases.

The effect of rs9930506 FTO gene polymorphism on obesity risk: a meta-analysis

Obesity is associated with polymorphisms of the fat mass and obesity associated gene (FTO). This meta-analysis aimed to investigate the association of the rs9930506 FTO gene polymorphism and obesity. To the best of our knowledge, this study is the first meta-analysis to evaluate the relation between FTO rs9930506 polymorphism and obesity.We searched PubMed, Web of Science, and Embase to identify studies investigating the relations between the rs9930506 FTO gene polymorphism and obesity risk. We pooled adjusted odds ratios (OR) as overall and in continent subgroups. A Fixed-effects model was used to analyze the results of these studies in dominant and recessive models.By examining 3337 obesity cases and 3159 healthy controls, we identified 8 eligible case-control studies. Considering the dominant model of inheritance, there was a relationship between the rs9939506 polymorphism and obesity (OR=1.34 [1.03- 1.74]). The association remained significant in the European subgroup (OR=1.68 [1.2-2.36]), but not in the Asian subgroup. Using the recessive model, we also found a significant relationship when the overall association was investigated (OR=2.47; 95% CI 1.56-3.91). In conclusion, this study identified that the carriers of the risk allele of FTO rs9930506 polymorphism are at higher risk for obesity.

Association of ABO Polymorphisms and Cancer/Cardiocerebrovascular Disease: a Meta-analysis

Background: ABO gene polymorphisms have been reported to be associated with the risk of multiple cancers and cardiocerebrovascular diseases. However, the results remained controversial. In this study, we conducted a systematic review and meta-analysis to clarify the association between two SNPs (rs505922 and rs657152) in ABO gene and cancers/cardiocerebrovascular diseases. Method: All eligible case-control studies come from PubMed, Embase and Web of Science up to Jan. 1, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding associations. Sensitivity analysis, publication bias assessment, and heterogeneity test were performed using STATA 12.0. Results: A total of eighteen articles involving twenty-nine case-control populations were included according to inclusion and exclusion criteria. Eleven populations (16,929 cases and 23,941 controls) were used to evaluate the relationship between rs505922 and overall cancers and nine populations (22,275 cases and 71,549 controls) were included to assess the association between rs505922 and cardiocerebrovascular diseases. The results showed a significant association between the rs505922 polymorphism and cancers (CvsT: OR=1.13, 95% CI=1.04-1.22, P=0.003), and cardiocerebrovascular diseases (OR=1.36, 95%CI=1.19-1.57, P<0.001). Four populations (5,158 cases and 7,021 controls) were included to evaluate association between rs657152 and cancers and five populations (8,105 cases and 6,712 controls) were included to estimate the relationship between rs657152 and cardiocerebrovascular diseases. The result of meta-analysis reveals that rs657152 was significantly associated with cancers (OR=1.16, 95%CI=1.09-1.24, P<0.001) and cardiocerebrovascular diseases (OR=1.54, 95%CI=1.24-1.92, P<0.001). Conclusion: Our study suggested that ABO polymorphisms may serve as a risk factor of cancers and cardiocerebrovascular diseases.

The Current Status of Quality of Reporting in Acupuncture Treatment Case Reports: An Analysis of the Core Journal in Korea

Objectives. The present study aimed to evaluate the overall quality of case reports concerning acupuncture treatment in Korea. Methods. We selected a representative Korean journal and retrieved eligible case reports on acupuncture treatment published from 2009 to 2015. We assessed the quality of reporting based on CAse REport (CARE) and STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) guideline checklists. Results. A total of 93 eligible case reports of acupuncture treatment were identified among the 107 articles screened. Overall quality of reporting in the case reports was generally acceptable (75.4% on CARE, 67.7% on STRICTA), but several crucial items remained substantially underreported. Conclusions. Endorsement of the CARE and STRICTA guidelines is needed to improve the completeness of reporting. Our findings will be helpful in developing a more appropriate reporting guideline for case reports in acupuncture treatment.

Dermatoglyphic meta-analysis indicates early epigenetic outcomes & possible implications on genomic zygosity in type-2 diabetes

Background: Dermatoglyphic studies, particularly those arising from the Dutch Hunger Winter Families Cohort, indicate an involvement of prenatal epigenetic insults in type-2 diabetes. However, the exact orchestration of this association is not fully understood. Herein is described a meta-analysis performed based on a belief that such an approach could shed some light as to the role of genetic & epigenetic influences in the etiology of type-2 diabetes. Methodology/principal findings: The study incorporated reports identified from PubMed, Medline, & Google Scholar databases for eligible case-control studies that assessed dermatoglyphics in type-2 diabetes cases relative to controls. Over 44,000 fingerprints & 2300 palm prints from around 4400 individuals were included in the analysis. Decreased loops patterns [OR= 0.76; 95% CI= (0.59, 0.98)], increased non-loop patterns [OR= 1.31; 95% CI= (1.02, 1.68)], and reduced absolute finger ridge counts [OR= -0.19; 95% CI= (-0.33, -0.04)] were significant findings among the diabetic group. These results are indicative of mild developmental deviances, with epigenetic insults significantly linked to early gestation wherein critical events &signaling pathways of the endocrine pancreas development are witnessed. Further, the increased loop patterns with decreased non-loop patterns were deemed as possible indicators of decreased genomic heterozygosity with concurrently increased homozygosity in the diabetic group, linked to reduced buffering capacities during prenatal development. Conclusions: Epigenetic insults primarily during the 1st trimester, to a lesser extent between the early-to-mid 2ndtrimester, but least likely linked to those beyond the mid-second trimester are evident in type-2 diabetes. It is recommended that future research aimed at expounding the prenatal origins of T2DM, as well as developing novel therapeutic methods, should focus on the early stages of endocrine pancreatic development.

Analyzing Association of theXRCC3Gene Polymorphism with Ovarian Cancer Risk

This meta-analysis aims to examine whether theXRCC3polymorphisms are associated with ovarian cancer risk. Eligible case-control studies were identified through search in PubMed. Pooled odds ratios (ORs) were appropriately derived from fixed effects models. We therefore performed a meta-analysis of 5,302 ovarian cancer cases and 8,075 controls from 4 published articles and 8 case-control studies for 3 SNPs ofXRCC3. No statistically significant associations betweenXRCC3rs861539 polymorphisms and ovarian cancer risk were observed in any genetic models. ForXRCC3rs1799794 polymorphisms, we observed a statistically significant correlation with ovarian cancer risk using the homozygote comparison (T2T2 versus T1T1: OR = 0.70, 95% CI = 0.54–0.90,P=0.005), heterozygote comparison (T1T2 versus T1T1: OR = 1.10, 95% CI = 1.00–1.21,P=0.04), and the recessive genetic model (T2T2 versus T1T1+T1T2: OR = 0.67, 95% CI = 0.52–0.87,P=0.002). ForXRCC3rs1799796 polymorphisms, we also observed a statistically significant correlation with ovarian cancer risk using the heterozygote comparison (T1T2 versus T1T1: OR = 0.91, 95% CI = 0.83–0.99,P=0.04). In conclusion, this meta-analysis shows that theXRCC3were associated with ovarian cancer risk overall for Caucasians. Asian and African populations should be further studied.